Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.